DE69733135D1 - Substituierte imidazole mit cytokinin-inhibirender wirkung - Google Patents

Substituierte imidazole mit cytokinin-inhibirender wirkung

Info

Publication number
DE69733135D1
DE69733135D1 DE69733135T DE69733135T DE69733135D1 DE 69733135 D1 DE69733135 D1 DE 69733135D1 DE 69733135 T DE69733135 T DE 69733135T DE 69733135 T DE69733135 T DE 69733135T DE 69733135 D1 DE69733135 D1 DE 69733135D1
Authority
DE
Germany
Prior art keywords
inhibirent
cytokinin
effect
substituted imidazole
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733135T
Other languages
English (en)
Other versions
DE69733135T2 (de
Inventor
J Liverton
W Butcher
A Claremon
T Bilodeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614190.8A external-priority patent/GB9614190D0/en
Priority claimed from GBGB9617897.5A external-priority patent/GB9617897D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69733135D1 publication Critical patent/DE69733135D1/de
Publication of DE69733135T2 publication Critical patent/DE69733135T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69733135T 1996-06-10 1997-06-06 Substituierte imidazole mit cytokinin-inhibirender wirkung Expired - Fee Related DE69733135T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US1948796P 1996-06-10 1996-06-10
US19487P 1996-06-10
GB9614190 1996-07-05
GBGB9614190.8A GB9614190D0 (en) 1996-07-05 1996-07-05 Substituted imidazoles having cytokine inhibitory activity
US2331296P 1996-07-31 1996-07-31
US23312P 1996-07-31
GBGB9617897.5A GB9617897D0 (en) 1996-08-28 1996-08-28 Substituted imidazoles having cytokine inhibitory activity
GB9617897 1996-08-28
PCT/US1997/009888 WO1997047618A1 (en) 1996-06-10 1997-06-06 Substituted imidazoles having cytokine inhibitory activity

Publications (2)

Publication Number Publication Date
DE69733135D1 true DE69733135D1 (de) 2005-06-02
DE69733135T2 DE69733135T2 (de) 2006-03-02

Family

ID=27451484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733135T Expired - Fee Related DE69733135T2 (de) 1996-06-10 1997-06-06 Substituierte imidazole mit cytokinin-inhibirender wirkung

Country Status (8)

Country Link
US (1) US5859041A (de)
EP (1) EP0906307B1 (de)
JP (1) JP3418624B2 (de)
AT (1) ATE294174T1 (de)
AU (1) AU708883B2 (de)
DE (1) DE69733135T2 (de)
ES (1) ES2239357T3 (de)
WO (1) WO1997047618A1 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
EP0994870A4 (de) 1997-06-19 2002-10-23 Smithkline Beecham Neue,durch einen aryloxyrest substituierte imidazolverbindungen
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002509537A (ja) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション 新規なシクロアルキル置換イミダゾール化合物
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1041989A4 (de) 1997-10-08 2002-11-20 Smithkline Beecham Corp Neue cycloalkenyl substituierte verbindungen
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
CN1302296A (zh) 1998-05-22 2001-07-04 史密丝克莱恩比彻姆公司 新的2－烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
WO2000019824A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
AU6476599A (en) * 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1495758A3 (de) * 1999-01-08 2005-04-13 3M Innovative Properties Company Zubereitungen, enthaltend Imiquimod oder andere Immunantwort modifizierende Verbindungen, zur Behandlung von mukosalen Erkrankungen
SK287112B6 (sk) * 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
MXPA02000314A (es) 1999-07-09 2004-06-22 Boehringer Ingelheim Pharma Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE60037597T2 (de) * 1999-11-22 2008-12-11 Smithkline Beecham P.L.C., Brentford Imidazol- Derivate
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
EP1332132B1 (de) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
AU2001266611A1 (en) * 2000-06-01 2001-12-11 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
DE60112312T2 (de) * 2000-09-21 2005-12-29 Smithkline Beecham P.L.C., Brentford Imidazolderivate als raf-kinase-inhibitoren
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
EP1364949A4 (de) 2001-02-02 2005-11-23 Takeda Pharmaceutical Jnk inhibitor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
CA2465759A1 (en) * 2001-12-11 2003-06-19 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering birb 796 bs
EP1480973B1 (de) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
NZ550148A (en) 2004-03-09 2010-07-30 Boehringer Ingelheim Pharma 3-'4-heterocyclyl-1,2,3,-triazol-1-yl-N-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NZ555474A (en) * 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN103012254A (zh) 2005-05-10 2013-04-03 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
KR20080033450A (ko) * 2005-07-30 2008-04-16 아스트라제네카 아베 증식성 질환의 치료에 사용하기 위한 이미다졸릴-피리미딘화합물
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
KR20080076968A (ko) * 2005-11-23 2008-08-20 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하는 방법
WO2007082554A1 (en) * 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
RU2497816C2 (ru) 2007-04-30 2013-11-10 Эббви Инк. Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1
JP5389785B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
PT2432767E (pt) * 2009-05-19 2013-07-25 Dow Agrosciences Llc Compostos e métodos para controlo de fungos
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
AU3592493A (en) * 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5310748A (en) * 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
AU3380997A (en) 1998-01-07
EP0906307B1 (de) 2005-04-27
JP3418624B2 (ja) 2003-06-23
JP2000515125A (ja) 2000-11-14
EP0906307A4 (de) 2002-05-29
DE69733135T2 (de) 2006-03-02
US5859041A (en) 1999-01-12
ATE294174T1 (de) 2005-05-15
AU708883B2 (en) 1999-08-12
EP0906307A1 (de) 1999-04-07
WO1997047618A1 (en) 1997-12-18
ES2239357T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
DE69733135D1 (de) Substituierte imidazole mit cytokinin-inhibirender wirkung
DE69637948D1 (de) Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
NO985864L (no) Nye anti-virale forbindelser
PE34096A1 (es) Derivado triciclico del pirazol
NZ503479A (en) halogen substituted styryl sulphone useful for treating cancer
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
DE69229738T2 (de) Antiseborrhoische zusammensetzung
FI934680A (fi) Arylmorfolin, framstaellning och anvaending
TR199900153T2 (xx) H�cre �o�almas�n� �nlemek i�in ikame edilmi� bisindolilmaleimitler.
KR880011149A (ko) N-1h-테트라졸-5-일-2-티오펜카르복사미드, n-1h-테트라졸-5-일-2-피롤카르복사미드,n-1h-테트라졸-5-일-2-푸란 카르복사미드
MX9802732A (es) Imidazolas substituidas que tienen actividad anticancer e inhibidora de citocina.
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
ATE124398T1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
KR950005921A (ko) 상처 치료를 촉진시키기 위한 조성물
ATE179890T1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
DK0580624T3 (da) Hidtil ukendte cytarabinderivater, fremstilling og anvendelse deraf
ECSP951499A (es) Compuestos ariltios

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee